Alirocumab

Studies of alirocumab in people

6 studies gave alirocumab to people and measured what changed

What changedDesignPeopleSource

down: Decreases CERT2Approximately 2 risk-score points lower than placebo

Treated cohort4 months4,285 peoplePatient cohortsAHA Scientific Sessions 2026 abstract, Nov 2, 2026

down: Decreases LDL cholesterol

Randomized trial52 weeks125 peopleBoth59 (51; 64) yearsPatients with acute coronary syndrome not achieving LDL-cholesterol target with statin therapyJournal of clinical medicine, Sep 29, 2026

up: Increases carotid plaque regressionregression proportions exceeded 30%

down: Decreases intraplaque neovascularization

down: Decreases LDL-C

Randomized trial12 months299 peoplePatients with high CVD risk with non-calcified plaque on the carotid arteryFrontiers in pharmacology, Aug 27, 2026

down: Decreases LDL cholesterol-34.1%

Trial1 month26 peopleAfter acute coronary syndrome, switched from inclisiranTerapevticheskii arkhiv, Mar 7, 2026

down: Decreases ceramide

Randomized trial265 peopleIn patients with acute myocardial infarctionCirculation. Genomic and precision medicine, Feb 10, 2026

down: Decreases major adverse cardiovascular eventsHR 0.78 (0.68-0.91) for ≥65 years

down: Decreases all-cause deathHR 0.77 (0.62-0.95) for ≥65 years

no change: Has no effect on adverse events

Randomized trial18,924 people≥65 yearsOlder adults; patients aged ≥65 years; consistent with <65 yearsEuropean heart journal, Nov 17, 2019